FOLD — Amicus Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.55bn
- $4.65bn
- $634.21m
Brief: Amicus Therapeutics Announces Positive Long-Term Data From Phase 3 Open-Label Extension Study Of At-Gaa In Late-Onset Pompe Disease At 19Th Annual Worldsymposium™ 2023
BTIG ups Amicus' PT on hopes of FDA review of muscle disorder drug in 2023
U.S. RESEARCH ROUNDUP-Adobe, GoDaddy, Shopify
Brief: Amicus Therapeutics Reports Provides 2023 Strategic Outlook
Brief: Amicus Therapeutics Enters Into License Agreement With Trustees Of University Of Pennsylvania
Amicus rises as EU health regulator backs muscle disorder therapy
Brief: Amicus Therapeutics Receives Positive CHMP Opinion For Pombiliti
EU health regulator backs Amicus therapy for muscle disorder (updated)
EU regulator endorses Amicus combination therapy for muscle disorder
U.S. RESEARCH ROUNDUP-Linkbancorp, Oyster Point Pharma, Viatris
Amicus Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Amicus Therapeutics Reports Q3 Loss Per Share Of $0.12
Amicus Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Insperity, Nikola, First Solar
U.S. STOCKS ON THE MOVE-Natgas, Wynn Resorts, Ascendis Pharma
Amicus falls after FDA extends muscle-disorder therapy review
FDA extends review of Amicus muscle disorder therapy for second time (updated)
Brief: U.S. FDA Defers Action On Filing For At-Gaa In Late-Onset Pompe Disease
FDA extends review of Amicus muscle disorder therapy for second time